Enliven Therapeutics closes merger, $165M raise

BOULDER —  Boulder-based oncology drug developer Enliven Therapeutics Inc. has completed its merger with Boston pharmaceutical company Imara Inc., a deal that takes the combined company public.

The deal, which paves the way for the merged organization to trade on the Nasdaq Global Select Market under the ticker symbol ELVN, is concurrent with a $165 million investment round led by Fairmount Funds and Venrock Healthcare Capital Partners.

As a result of the investment, Enliven is “expected to have a cash runway through multiple clinical milestones and into early 2026,” the company said. 

BizWest reported late last year that the combined company anticipated having…